Genovate Financial Statements From 2010 to 2024

4130 Stock  TWD 21.75  0.05  0.23%   
Genovate Biotechnology financial statements provide useful quarterly and yearly information to potential Genovate Biotechnology Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Genovate Biotechnology financial statements helps investors assess Genovate Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Genovate Biotechnology's valuation are summarized below:
Genovate Biotechnology Co does not presently have any fundamental trends for analysis.
Check Genovate Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genovate Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Genovate financial statements analysis is a perfect complement when working with Genovate Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Genovate Biotechnology Technical models . Check out the analysis of Genovate Biotechnology Correlation against competitors.

Genovate Biotechnology Co Company Current Valuation Analysis

Genovate Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Genovate Biotechnology Current Valuation

    
  3.16 B  
Most of Genovate Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genovate Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Genovate Biotechnology Co has a Current Valuation of 3.16 B. This is 77.97% lower than that of the Healthcare sector and 31.9% lower than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 80.97% higher than that of the company.

Genovate Biotechnology Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Genovate Biotechnology's current stock value. Our valuation model uses many indicators to compare Genovate Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genovate Biotechnology competition to find correlations between indicators driving Genovate Biotechnology's intrinsic value. More Info.
Genovate Biotechnology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.68  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genovate Biotechnology Co is roughly  1.47 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genovate Biotechnology's earnings, one of the primary drivers of an investment's value.

About Genovate Biotechnology Financial Statements

Genovate Biotechnology investors use historical fundamental indicators, such as Genovate Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Genovate Biotechnology. Please read more on our technical analysis and fundamental analysis pages.

Pair Trading with Genovate Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genovate Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genovate Biotechnology will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Genovate Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genovate Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genovate Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genovate Biotechnology Co to buy it.
The correlation of Genovate Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genovate Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genovate Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genovate Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Genovate Stock Analysis

When running Genovate Biotechnology's price analysis, check to measure Genovate Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genovate Biotechnology is operating at the current time. Most of Genovate Biotechnology's value examination focuses on studying past and present price action to predict the probability of Genovate Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genovate Biotechnology's price. Additionally, you may evaluate how the addition of Genovate Biotechnology to your portfolios can decrease your overall portfolio volatility.